PRAX
Praxis Precision Medicines, Inc. Health Care Pharmaceutical Preparations Russell 3000
$285.93Close
$7.2BMarket cap
$164.09 – $386.3352-week range
Nov 9, 2026Next report · before the open
Highlights
Strengths
- Tight base near its pivot pullbacks 30% → 21%; 4.4% below its $299.12 pivot
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 48 · weaker than 52% of stocks over 12 months
- Far from its high 26% below its 52-week high
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
26%
1wk
up 13.0%
price change
1mo
down 1.8%
price change
12-month return
up 42%
market up 11% ·
its own up 35%
F-score
—
— Not assessed
Altman Z
70.17
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
8.2×
price / book
Earnings yield
down 4.8%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
down 100%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 46%
return on equity
Free cash margin
—
-$249.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.5%
$12.90 a day · 2×ATR $260.13
RS
48 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.67
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Contractions
2
30% → 21%
Pivot
$299.12
4.4% below
Volume dry-up
1.1×
10 vs 50 sessions
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 29.7% over the year, from 19m to 25m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 100.0% over the year.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+13% vs market2 sessions after results
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $2.4M | $8.6M | $0 |
| Operating income | -$62.0M | -$167.3M | -$215.0M | -$126.4M | -$200.2M | -$326.2M |
| Net income | -$61.8M | -$167.0M | -$214.0M | -$123.0M | -$183.0M | -$303.0M |
| Net margin | — | — | — | -5027% | -2140% | — |
| Earnings per share | -$103.56 | -$58.98 | -$69.64 | -$18.65 | -$10.22 | -$13.46 |
| Free cash flow | -$52.6M | -$125.6M | -$185.5M | -$111.2M | -$131.8M | -$249.1M |
| Free cash margin | — | — | — | -4544% | -1540% | — |
| Cash | $296.6M | $138.7M | $61.6M | $81.3M | $215.4M | $357.3M |
| Shareholders' equity | $287.5M | $250.8M | $76.1M | $69.7M | $445.4M | $878.1M |
| Shares outstanding | 2.55m | 3.02m | 3.29m | 8.79m | 19.42m | 25.20m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 2, 2025 | Quarterly ↗ | Mar 31, 2025 | 32d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Mar 5, 2024 | Annual ↗ | Dec 31, 2023 | 65d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results · Regulation FD ↗ |
| Jul 7, 2026 | Other events ↗ |
| Jul 2, 2026 | Auditor change ↗ |
| Jun 29, 2026 | Other events ↗ |
| Jun 22, 2026 | Other events ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| Jun 1, 2026 | Other events ↗ |
| May 7, 2026 | Results · Regulation FD ↗ |
| Apr 14, 2026 | Other events ↗ |
| Apr 6, 2026 | Other events ↗ |
| Feb 19, 2026 | Results ↗ |
| Jan 8, 2026 | Director or officer change ↗ |